ZyVersa Therapeutics, Inc.
ZVSA
$0.20
$0.014.17%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 96.57% | -795.65% | 2.02% | -58.75% | 40.79% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.90% | 9,421.17% | 22.16% | -44.10% | 71.31% |
| Change in Net Operating Assets | -61.85% | -0.56% | 51.54% | 584.63% | -104.20% |
| Cash from Operations | 70.59% | 7.54% | 14.13% | -45.89% | -97.80% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 1,025,850.00% | -- | -- | 267.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.39% | -955.87% | -100.97% | 543.44% | -98.57% |
| Cash from Financing | -100.67% | 10,624.29% | -100.96% | -29.36% | 324.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.49% | 129.62% | -2,009.93% | -94.28% | 41,311.76% |